16th Annual Aventis Pharma Hypertension Research Clinical Fellowship Program Award
2001; Lippincott Williams & Wilkins; Volume: 37; Issue: 2 Linguagem: Inglês
10.1161/01.hyp.37.2.811
ISSN1524-4563
Tópico(s)Ion Transport and Channel Regulation
ResumoHomeHypertensionVol. 37, No. 216th Annual Aventis Pharma Hypertension Research Clinical Fellowship Program Award Free AccessOtherPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessOtherPDF/EPUB16th Annual Aventis Pharma Hypertension Research Clinical Fellowship Program Award Originally published1 Feb 2001https://doi.org/10.1161/01.HYP.37.2.811Hypertension. 2001;37:811–823The purpose of this program and research award is to stimulate physicians-in-training to pursue a career in clinical research in hypertension. The research fellow must be conducting work in which he or she is the major senior investigator in any area including clinical or laboratory aspects of the hypertensive diseases. The fellow’s work would be supervised by the director of the research training program (the mentor), but the conduct of the investigation is primarily by the research fellow. The winning presentation receives $3,000 and the fellow’s mentor receives $25,000 to support the clinical investigative training of a research fellow the following year.Dr Patricia L. Turner completed her undergraduate work at the University of Pennsylvania, in Philadelphia, and received her medical degree from Wake Forest University School of Medicine, in Winston Salem, North Carolina in 1996. Dr Turner is currently a third-year general surgery resident at Howard University Hospital in Washington, DC. From 1998 to 2000, she was a senior staff fellow in Dr Mark Knepper’s laboratory in the Laboratory of Kidney and Electrolyte Metabolism in the National Heart, Lung and Blood Institute of the NIH. Her work with Dr Knepper focused on dysregulation of sodium transport in the kidney. Using a targeted proteomics approach, Dr Turner’s research demonstrated specific changes in regulation of individual transporters along the nephron. Her work for the Aventis Pharma Hypertension Research Award explored the way in which inhibition of nitric oxide synthase is related to the pathophysiology of hypertension.Previous Recipients of the Hoechst Marion Roussel Hypertension Research Clinical Fellowship Award1999David Geller, MD, PhD,Yale University School of Medicine,Mentor: Richard Lifton1998Martin Matsubara, MD,University of Virginia,Mentor: Coleen McNamara1997W. Reid Litchfield, MD,Harvard Medical School/Brigham and Women’s Hospital,Mentor: Robert G. Dluhy1996David B. Simon, MD,Yale University School of Medicine,Mentor: Richard Lifton1995Joni H. Hansson, MD,Yale University School of Medicine,Mentor: Richard Lifton1994John Krege, MD,University of North Carolina,Mentor: Oliver Smithies1993Luis A. Juncos, MD,Henry Ford Hospital,Mentors: Sadayoski Ito andOscar A. Carretero1992Amy L. Tucker, MD,University of Virginia,Mentor: Kevin R. Lynch1991Elizabeth Gilbert D’Angelo, MD,University of Virginia,Mentor: Christopher M. Rembold1990Bruno Escalante, MD,New York Medical College,Mentor: John C. McGiff1989Allen Everett, MD,University of Virginia,Mentor: Ariel Gomez1988Allen J. Naftilan, MD,Harvard Medical School/Brigham and Women’s Hospital,Mentor: Victor J. Dzau1987Christopher M. Rembold, MD,University of Virginia,Mentor: Carlos R. Ayers1986Judith E. Kalinejak, MD, PhD,Stanford Medical Center,Mentor: Andrew J. Perlman1985Gail K. Adler, MD, PhD,Harvard Medical School/Peter Bent Brigham Hospital,Mentor: Gordon H. Williams1984Christine Seidman, MBBS,Harvard Medical School/Massachusetts General Hospital,Mentor: Robert M. GrahamIrvine Page–Alva Bradley Lifetime Achievement Award 2000For combating hypertension through exemplary research, education, and service, Patrick J. Mulrow, MD is the 2000 Irvine Page-Alva Bradley Lifetime Achievement Award recipient.Dr Mulrow is a Professor Emeritus in the Department of Medicine at the Medical College of Ohio at Toledo. He received his medical degree from Cornell University Medical College in New York in 1951. He later joined the faculty at Yale University Medical School as an instructor, eventually becoming a full professor and Chief of the Division of Endocrinology. From there, he became Professor and Chairman of the Department of Medicine at the Medical College of Ohio.As an American Heart Association volunteer, Dr Mulrow has served on various committees, including the Scientific Sessions Program Committee and the National Research Committee, and he was elected President of the Central Society for Clinical Research. He has served on numerous research committees of the NIH, AHA, and VA. He was also a member of the Executive Committee of the International Society of Hypertension and the Inter-American Society of Hypertension. He is currently Secretary General of the World Hypertension League.Dr Mulrow’s research has made many outstanding contributions to our understanding of the pathogenesis and treatment of hypertension, especially in the area of the renin-angiotensin-aldosterone system. Dr Mulrow was, for example, one of the first investigators to discover the stimulatory effect of angiotensin II on aldosterone selection.It is for these many accomplishments - and many others during his illustrious career - that the American Heart Association Council for High Blood Pressure Research presents Dr Patrick J. Mulrow the 2000 Irvine Page-Alva Bradley Lifetime Achievement Award.Past Recipients of the Lifetime Achievement Award1999Myron H. Weinberger, MD1998David H.P. Streetan, Dphil1997Norman M. Kaplan, MD1996Edward George Biglieri, MD1995William Francis Ganong, MD1994Stevo Julius, MD, DSc1993Edward D. Frohlich, MD1992Ray W. Gifford, Jr, MD1991Harriet P. Dustan, MD1990Aram V. Chobanian, MDNovartis Award for Hypertension Research 2000In recognition of outstanding contributions made in hypertension research, the Novartis (formerly CIBA) Award has been presented at the annual meeting of the Council for High Blood Pressure Research since 1975. The Novartis Award continues the tradition of the Ciba Award and the Stouffer Prize, first awarded to Ernst Klenk, MD, and Harry Goldblatt, MD, in 1966. In 2000, the Novartis Award was presented to Hans R. Brunner, MD, Jay N. Cohn, MD, and Haralambos Gavras, MD.Dr Haralambos Gavras is Professor of Medicine at Boston University School of Medicine where he is also Chief of Hypertension and Atherosclerosis and Director for the Specialized Center of Research in Molecular Genetics of Hypertension. He obtained his medical degree from Athens University School of Medicine in Greece and his postgraduate training at the Western Infirmary, Glasgow, United Kingdom, as a British Council Scholar.Dr Gavras’ research on the renin-angiotensin system played a major role in the development and clinical use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II antagonists for the treatment of hypertension and congestive heart failure in humans. Dr Gavras, along with Dr Hans Brunner, first introduced the use of ACE inhibitors and angiotensin II blockers for the treatment of hypertension and heart failure in the series of clinical studies published in the New England Journal of Medicine, The Journal of the American Medical Association, and Circulation.Prior to these groundbreaking clinical studies, Dr Gavras also demonstrated in experimental animals the powerful role of angiotensin II receptor blockers and ACE inhibitors in lowering blood pressure, especially in animals maintained on low sodium intake. Additional experimental and clinical studies by Dr Gavras and his colleagues in the 1970s and early 1980s helped to elucidate the pathogenic mechanisms, hemodynamic responses, and hormonal patterns that characterize various stages of hypertension, ischemic heart disease, and heart failure and the important role of blocking the renin-angiotensin system in treating these abnormalities. These early studies, which initially received skepticism by the scientific community, were soon enthusiastically adopted and confirmed by other investigators. Dr Gavras’ and Dr Brunner’s research paved the way for the widespread use of ACE inhibitors and angiotensin II antagonists in the treatment of hypertension, ischemic heart disease, and heart failure. The enormous clinical impact of their work is evident by the numerous multicenter, multinational trials that have subsequently proven the capacity of ACE inhibitors and angiotensin II antagonists to diminish cardiovascular morbidity and mortality.Dr Gavras has received numerous awards for his research and is past president of the Inter-American Society of Hypertension, past chairman of the Council for High Blood Pressure of the American Heart Association, and current president elect of the American Society of Hypertension. He has been on the faculty of Boston University since 1975 and is the author of over 550 publications. Dr Gavras is receiving the Novartis Award of The Council for High Blood Pressure Research, American Heart Association for “his groundbreaking work to introduce the use of angiotensin II antagonists and angiotensin converting enzyme inhibitors in the treatment of hypertension and heart failure in humans.”Novartis Award for Hypertension Research 2000Dr Hans R. Brunner is Professor of Medicine at Lausanne University, Switzerland, and Head of the Division of Hypertension and Vascular Medicine at the University Hospital. He received his medical degree from Basel University and trained at Geneva University in internal medicine. He also worked as a research fellow and as an Assistant Professor at Columbia University from 1969–1974.During this period, his research led to the observation that angiotensin II acts as a risk factor for cardiovascular complications in hypertensive patients. Together with Dr Haralambos Gavras, Dr Brunner conducted a pioneering series of experiments to investigate the role of angiotensin II antagonists and angiotensin-converting enzyme (ACE) inhibitors in experimental animals and humans with hypertension and congestive heart failure. Their groundbreaking work in experimental animals provided the basis for subsequent treatment of humans with hypertension or congestive heart failure with these pharmacological inhibitors of the renin-angiotensin system. Their work demonstrated the powerful role of blocking the renin-angiotensin system in lowering blood pressure and improving cardiovascular function in hypertension. These seminal studies opened the way for subsequent research by many investigators around the world, leading eventually to the acceptance of the concept that ACE inhibition and angiotensin II blockade are powerful tools for cardiovascular protection. The scientific importance and clinical impact of their research is indicated by the large number of multi-center trials that it has spawned, such as CONSENSUS, SOLVD, SAVE, etc. These studies have clearly documented the ability of ACE inhibition to diminish cardiovascular morbidity and mortality.Dr Brunner has remained in the forefront of basic and clinical cardiovascular research. His work has led to the synthesis of novel pharmacological tools; he has received national and international awards for his work, and he has published more than 600 papers. Dr Brunner is receiving the Novartis Award of The Council for High Blood Pressure Research, American Heart Association for “his groundbreaking work to introduce the use of angiotensin II antagonists and angiotensin converting enzyme inhibitors in the treatment of hypertension and heart failure in humans.”Novartis Award for Hypertension Research 2000Dr Jay N. Cohn is Professor of Medicine at the University of Minnesota Medical School where he is also Head of the Cardiovascular Division. Dr Cohn received his medical degree from Cornell University Medical College and subsequently trained at Beth Israel Hospital in Boston and at Georgetown University Medical Center.Dr Cohn’s work began with a series of basic and clinical studies on circulatory shock. He recognized early the value of hemodynamic monitoring and identified specific hemodynamic patterns that were not being properly treated without bedside hemodynamic measurements. He initiated a series of mechanistic studies of shock and provided a therapeutic approach that has helped in recent years to reduce the incidence and mortality from shock. His observations on ventricular dysfunction in cardiogenic shock have served as a foundation for the current clinical diagnosis and treatment of myocardial infarction that is now standard practice in coronary care units. He also demonstrated a remarkable hemodynamic benefit of vasodilator therapy in patients with left ventricular failure, and the outgrowth of these observations was the first large scale clinical trial of vasodilator therapy after acute myocardial infarction, a study that he developed and conducted within the Veterans’ Administration Cooperative Studies Program. His observations with nitroprusside also led him to evaluate this drug therapy in patients with chronic decompensated heart failure, and he later introduced the vasodilator combination of isosorbide nitrate and hydralazine in the first long-term mortality trial in heart failure (V-HeFT I), which he designed and conducted. Dr Cohn was also one of the first to explore the role of neurohumoral factors in congestive heart failure. His group’s demonstration of a direct relationship between mortality rate and plasma norepinephrine served as a basis for the use of β-blocker therapy for heart failure. Dr Cohn’s recognition of a reduction in left ventricular chamber size as a correlate of mortality reduction in V-HeFT I led him to develop an animal model of left ventricular enlargement caused by localized damage of the heart. He found in this model that therapy with nitrates and ACE inhibitors prevented the left ventricular remodeling, and these studies have provided the pathophysiological basis for the use of these drugs in the treatment of human heart failure. Dr Cohn’s outstanding work in basic science and clinical therapy of congestive heart failure has lead to several national and international awards, and he continues an active research program. Dr Cohn is receiving the Novartis Award of the Council for High Blood Pressure Research, American Heart Association “for his seminal work on the pathophysiology and treatment of heart failure.”Past Recipients of the Novartis Award1999Richard P. Lifton, MD, PhD1998Masashi Yanagisawa, MD, PhD1997Oscar A. Carretero, MDAllen W. Cowley, Jr, PhDDonald D. Heistad, MDPast Recipients of the CIBA Award1996Robert J. Lefkowitz, MDOliver Smithies, Dphil1995Louis J. Ignarro, PhDSalvador Moncada, MD, PhD, DSc, FRS1994Adolfo J. DeBold, OC, PhD, FRSCErvin G. Erdos, MD1993John Paul Rapp, DVM, PhD1992Detlev Ganten, MD, PhD1991Salomon Z. Langer, MDAndrew P. Somlyo, MDAvril V. Somlyo, PhD1990Francis M. Abboud, MDMichael J. Brody, PhD1989Edgar Haber, MD1988Robert R. Furchgott, PhDFerid Murad, MD, PhD1987Donald J. Reis, MD1986Maurice B. Burg, MDJohn C. McGiff, MDE. Eric Muirhead, MD1985Pierre Corvol, MDTadashi Inagami, PhDJoel Menard, MD1984David F. Bohr, MD1983David W. Cushman, PhDSergio Henrique Ferreira, MD, PhDMiguel A. Ondetti, PhD1982Kyuzo Aoki, MDKozo Okamoto, MDYukio Yamori, MD1981Edward D. Freis, MDWilliam B. Kannel, MD1980Bjorn U.G. Folkow, MD, PhDArthur C. Guyton, MD1979Karl H. Beyer, Jr, MDJames M. Sprague, PhD1978Louis Tobian, Jr, MD1977John A. Luetscher, MDJames F. Tait, FRSSylvia A.S. Tait, BSc, FRS1976Raymond P. Ahlquist, PhDJames Q. Black, MD1975Lewis K. Dahl, MDJames O. Davis, MDWalter Kempner, MDPast Recipients of the Stouffer Prize1972Vincent P. Dole, MDJohn W. Gofman, MDRobert S. Gordon, Jr, MDJohn L. Oncley, MD1970Irvine H. Page, MDSir George Pickering, MD1969Jerome W. Conn, MDJacques Genest, MDFranz Gross, MDJohn H. Laragh, MD1968F. Merlin Bumpus, PhDW. Stanley Peart, MD1967John W. Comforth, MDUS von Euler, MDPeter Holtz, MDGeorge J. Popjak, MD1966Ernst Klenk, MDHarry Goldblatt, MDHarry Goldblatt Award 2000The Goldblatt Award is presented each year to the author(s) of the paper(s) from last year’s meeting judged by the Publication Committee of the Council for High Blood Pressure Research to represent the most significant new contribution to the understanding of the causes and/or consequences of hypertension. The award is named for the eminent hypertension researcher Dr Harry Goldblatt and is supported by a generous donation to the council from his family. Included with the award is a $1,000 honorarium and a commemorative plaque.The 2000 Goldblatt Award was presented to Dr Jane Reckelhoff who is an associate professor in the Department of Physiology and Biophysics at the University of Mississippi Medical Center in Jackson. She has been a Fellow of the Council for High Blood Pressure since 1995. Dr Reckelhoff has been studying mechanisms responsible for aging of the kidney with emphasis on the roles of nitric oxide (NO) and oxidative stress in the aging injury. She has determined that aging in the rat is associated with reductions in NO production and serum l-arginine levels, and yet the renal microvascular response to NO synthase inhibition is exaggerated. When l-arginine is increased in aging animals, the renal function is protected from aging injury. Similarly, long-term treatment (9 months) of aging rats with vitamin E improved renal function and protected against oxidative stress, such as the increase in renal F2-isoprostanes, increase in both advanced glycation end products (AGEs) and the receptor for AGEs, and the induction of heme oxygenase 1. There are gender differences in the aging injury in humans and rats and the role that gender plays in aging renal injury and hypertension has been a focus of Dr Reckelhoff’s work in recent years.Dr Reckelhoff performed the first systematic studies into the mechanisms responsible for the gender difference in blood pressure in spontaneously hypertensive rats (SHR). She determined that the higher blood pressure in male SHR is mediated via the androgen receptor and that overiectomized female rats treated long term with testosterone also exhibit higher blood pressure than do intact or untreated overiectomized females. She has also demonstrated that the male SHR and overiectomized female SHR exhibit a shift in the pressure-natriuresis relationship to higher blood pressures. In the work presented for the Goldblatt Award, Dr Reckelhoff performed studies to determine the role that the renin-angiotensin system (RAS) played in the gender differences in blood pressure in SHR. The data showed that long-term angiotensin converting enzyme inhibition removed the gender difference in blood pressure in the SHR. These data strongly suggested that the RAS played an important role in the higher blood pressure in all SHR, regardless of gender. However, because the blood pressure decreased more with converting enzyme inhibition in the male and overiectomized female SHR treated with testosterone than in the 25 to 30 mm Hg gender difference in the blood pressure between male and female SHR was also mediated by the RAS. Finally, the data showed that without an intact RAS, testosterone was unable to increase blood pressure in overiectomized SHR, again supporting the important role of RAS in the gender difference in BP and SHR. These studies mark the beginning of important studies into the possible mechanisms by which men have higher blood pressures than do premenopausal women.Past Recipients of the Goldblatt Award1999Craig H. Gelband, PhD1998Edward W. Inscho, PhD1997Kristof Graf, MDSandra Pfister, PhD1996Ryuichi Morishita, MD, PhD1995Dewan S.A. Majid, MD, PhD1994R. Davis Manning, Jr, PhD1993William J. Stekiel, PhD1992Albert P. Rocchini, MD1991Donald W. Ducharme, PhDDouglas W. Harris, MDJames H. Ludens, MDFrederic Mandel, MDW. Rodney Mathews, MD1990Pavel Hamet, MD, PhD1989John M. Hamlyn, PhD1988Albert J. Nasjletti, MD1987Victor J. Dzau, MD1986Willa A. Hseuh, MD1985Daniel T. O’Connor, MD1984John E. Hall, PhD1983Gaetan Thibault, PhD1982Gunner Gothberg, MD1981Michael J. Antonaccio, PhD1980Donald D. Heistad, MD1979Carlos Ferrario, MDArthur C. Corcoran Memorial Lecturer 2000Friedrich C. Luft, MD is Professor of Medicine and Head of the Nephrology and Hypertension section at the Franz Volhard Clinic, Chief of the First Clinic for Internal Medicine, Klinikum Buch, Medical Faculty of the Charité Humboldt University of Berlin. He is a graduate of Colorado College, Colorado Springs, and Jefferson Medical College, Philadelphia. He trained in Internal Medicine and Nephrology at Indiana University School of Medicine, where he was a member of the faculty for 15 years. Together with Joe Christian, Clarence Grim, Judy Miller, and Myron Weinberger, Luft was involved in genetic studies of hypertension and salt homeostasis long before such studies became in vogue. During a sabbatical in Heidelberg, he worked with Thomas Unger on autonomic cardiovascular regulation and with Detlev Ganten on regulatory peptides. Luft’s interests are broad and cover the entire gamut from cellular to patient-oriented research.In 1992, Luft was invited to assume his present position in Berlin, which includes a close affiliation with the Max Delbrück Center for Molecular Medicine. His specific research mission is to focus on the complex molecular genetics of cardiovascular diseases. A part of this mission included the establishment of a twin cohort for cardiovascular research. Together with Andreas Busjahn, Hans-Dieter Faulhaber, Herbert Schuster, and above all, highly motivated and cooperative with twin subjects, Luft used the classical twin model to establish the influence of genetic variance and then relied on identity-by-descent linkage, association, and transmission-dysequilibrium testing to gain molecular genetic insights. The project has been useful in studies of hypertension, lipid metabolism, electrocardiographic studies (QT interval), heart size, and other pertinent cardiovascular questions. Twin studies were the topic of this year’s Corcoran Lecture.Beyond research-related issues, Dr Luft enjoys patient rounds, teaching students, and close contact with clinical and research fellows. His clinical duties cover the entire spectrum of internal medicine and force him to frequent encounters with the ABIM recertification process in general internal medicine and two subspecialties. Dr Luft considers himself fortunate in being able to enjoy all three aspects of the all-around clinical investigator: research, training, and patient care.Past Arthur C. Corcoran Memorial Lecture Recipients1999Norman K. Hollenberg, MD, PhD1998Suzanne Oparil, MD1997Alberto Nasjletti, MD1996Edward D. Frohlich, MD1995Masashi Yanigisawa, MD, PhD1994Salvador Moncada, MD, PhD1993Haralambos Gavras, MD1992Stevo Julius, MD1991Detlev Ganten, MD1990Hugh E. deWardener, MD1989Aram V. Chobanian, MD1988Harriet P. Dustan, MD1987Edgar Haber, MD1986Robert J. Lefkowitz, MD1985Robert C. Tarazi, MD1984Wai Yiu Cheung, PhD1983Michael S. Brown, MDJoseph L. Goldstein, MD1982Pierre L. Corvol, MD1981Bengt Samuelsson, MD1980Frederic Bartter, MD1979E. Eric Muirhead, MD1978J. Ian S. Robertson1977Borgie Johansson, MDMerck New Investigator Award 2000The purpose of the Merck New Investigator Award is to encourage young investigators to undertake or continue hypertension research and participate in the conference. The award permits a young investigator to travel to the annual meeting and to present research orally or in poster format and to engage in discussion with senior investigators. The candidates are young investigators (MD or PhD), fellows in training, and academicians who hold an academic rank no higher than that of instructor at the time of submission of an abstract. Each awardee (up to 10) receives $1,000.The Merck New Investigator Award/Latin America is presented with the same criteria to up to five qualified new investigators who plan to pursue their careers in Latin America. Each awardee receives $2,000.New Fellows, Council for High Blood Pressure 2000FellowsNorma C. Adragna, PhDGail K. Adler, PhDLawrence J. Appel, MD, MPHFernando Costa, MDDr. Stanley FranklinMartha N. Hill, RN, PhDPavel J. Levy, MDJames N. Martin, MDVictoria F. Norwood, MDL. Michael Prisant, MD, FACC, FACPRicardo Rocha, MDRose Marie Robertson, MDJoseph I. Shapiro, MDChristie P. Thomas, MBBSNosratola D. Vaziri, MDWeiguo Zhang, MD, PhDAi-Ping Zou, MD, PhDInternational FellowsGiulio Ceolotto, MDJens Jordon, MDKazuomi Kario, MD, PhDPaul Lijnen, PhDEmpar Lurbe, MDHidehiro Matsuoka, MD, PhDManuel Diamantino Pires Bicho, MD, PhDJia Long Zhuo, MD, PhDDownload figureDownload PowerPoint Figure 1. Patricia L. TurnerDownload figureDownload PowerPoint Figure 2. Patrick J. MulrowDownload figureDownload PowerPoint Figure 3. Haralambos GavrasDownload figureDownload PowerPoint Figure 4. Hans R. BrunnerDownload figureDownload PowerPoint Figure 5. Jay N. CohnDownload figureDownload PowerPoint Figure 6. Jane ReckelhoffDownload figureDownload PowerPoint Figure 7. Friedrich C. LuftDownload figureDownload PowerPoint Previous Back to top Next FiguresReferencesRelatedDetails February 2001Vol 37, Issue 2 Advertisement Article InformationMetrics https://doi.org/10.1161/01.HYP.37.2.811 Originally publishedFebruary 1, 2001 PDF download Advertisement
Referência(s)